Recently,Jiu’an Medical(002432)announcementAccording to the report, the subsidiary New Crown Antigen home self-test OTC kit has been authorized by the US FDA EUA. After the product has obtained the U.S. Emergency Use Authorization (EUA), it can be sold in the U.S. and countries/regions that recognize the U.S. EUA during the U.S. public health emergency. also,Jiu’an MedicalReplied on the Shenzhen Stock Exchange’s interactive platform that the company’s new crown antigen home self-test OTC kit products have been sold to the C-end and B-end at the same time by the subsidiary iHealth USA at the beginning of last week. The company is actively contacting and following up with customers from all parties. Orders.The release of related information detonatedJiu’an MedicalFor the stock price, the company has gained 8 consecutive daily limit. Does the company use the interactive platform to cater to market hotspots and speculate on the company’s stock price? On November 24th, in an interview with a reporter from Beijing Business Daily, Jiu’an Medical Secretary Wu Tong said that the information we disclosed on Interactive Easy is the information that has been publicized in the announcement or on the FDA website. We have no information other than this information. Other information has been disclosed, and there is no deliberately driving up or speculating on the stock price.
(Source: Beijing Commercial Daily)
Article source: Beijing Commercial Daily
Editor in charge: 3
Original title: Is there any use of the interactive platform to speculate the company’s stock price?Jiu’an Medical Secretary Wu Tong responded: there is no deliberately driving up the stock price
Solemnly declare: The purpose of this information is to spread more information, and it has nothing to do with this stand.
Scan the QR code to follow
Oriental Wealth Official Website WeChat